Nanoparticle therapeutics: a personal perspective

被引：142

作者：

McNeil, Scott E. ^{[1
]}

机构：

[1] NCI, Nanotechnol Characterizat Lab, Imaging & Nanotechnol Grp, SAIC Frederick Inc, Frederick, MD 21701 USA

来源：

WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY | 2009年 / 1卷 / 03期

基金：

美国国家卫生研究院;

关键词：

DRUG-DELIVERY; DENDRIMERS; BIODISTRIBUTION;

D O I：

10.1002/wnan.6

中图分类号：

TB3 [工程材料学];

学科分类号：

082905 [生物质能源与材料];

摘要：

Nanotechnology offers many potential benefits to cancer research through passive and active targeting, increased solubility/bioavailablility, and novel therapies. However, preclinical characterization of nanoparticles is complicated by the variety of materials, their unique surface properties, reactivity, and the task of tracking the individual components of multicomponent, multifunctional nanoparticle therapeutics in in vivo studies. There are also regulatory considerations and scale-up challenges that must be addressed. Despite these hurdles, cancer research has seen appreciable improvements in efficacy and quite a decrease in the toxicity of chemotherapeutics because of 'nanotech' formulations, and several engineered nanoparticle clinical trials are well underway. This article reviews some of the challenges and benefits of nanomedicine for cancer therapeutics and diagnostics. (C) 2009 John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2009 1 264-271

引用

页码：264 / 271

页数：8

共 24 条

[1]

Drug delivery systems: Entering the mainstream [J].

Allen, TM ;

Cullis, PR .

SCIENCE, 2004, 303 (5665) :1818-1822

[2]

Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice [J].

Bibby, DC ;

Talmadge, JE ;

Dalal, MK ;

Kurz, SG ;

Chytil, KM ;

Barry, SE ;

Shand, DG ;

Steiert, M .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 293 (1-2) :281-290

[3]

Chamberlain P, 2003, Dev Biol (Basel), V112, P3

[4]

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel [J].

Desai, N ;

Trieu, V ;

Yao, ZW ;

Louie, L ;

Ci, S ;

Yang, A ;

Tao, CL ;

De, T ;

Beals, B ;

Dykes, D ;

Noker, P ;

Yao, R ;

Labao, E ;

Hawkins, M ;

Soon-Shiong, P .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1317-1324

[5]

Immunological properties of engineered nanomaterials [J].

Dobrovolskaia, Marina A. ;

Mcneil, Scott E. .

NATURE NANOTECHNOLOGY, 2007, 2 (08) :469-478

[6]

Fang J, 2003, ADV EXP MED BIOL, V519, P29

[7]

Effect of pegylation on pharmaceuticals [J].

Harris, JM ;

Chess, RB .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (03) :214-221

[8]

Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance [J].

Hirsch, LR ;

Stafford, RJ ;

Bankson, JA ;

Sershen, SR ;

Rivera, B ;

Price, RE ;

Hazle, JD ;

Halas, NJ ;

West, JL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (23) :13549-13554

[9]

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models [J].

Kirpotin, Dmitri B. ;

Drummond, Daryl C. ;

Shao, Yi ;

Shalaby, M. Refaat ;

Hong, Keelung ;

Nielsen, Ulrik B. ;

Marks, James D. ;

Benz, Christopher C. ;

Park, John W. .

CANCER RESEARCH, 2006, 66 (13) :6732-6740

[10]

Macromolecular MRI contrast agents with small dendrimers: Pharmacokinetic differences between sizes and cores [J].

Kobayashi, H ;

Kawamoto, S ;

Jo, SK ;

Bryant, HL ;

Brechbiel, MW ;

Star, RA .

BIOCONJUGATE CHEMISTRY, 2003, 14 (02) :388-394

← 1 2 3 →